Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009905 · ClinicalTrials.gov registry record
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
A clinical trial of Hypopituitarism and Growth Hormone Disorder, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 22,960
- Enrollment target
- 1
- Study location
NCT01009905: Completed study of Hypopituitarism and Growth Hormone Disorder, sponsored by Novo Nordisk A/S.
NCT01009905 is a study of Hypopituitarism and Growth Hormone Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 22,960 participants, above the 32-participant average among 3 other Hypopituitarism trials with a reported enrollment target (71650% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01009905, a study of Hypopituitarism and Growth Hormone Disorder, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 22,960 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is conducted in the United States of America (USA). The aim of this observational study is to collect data concerning the treatment outcomes and safety for children and adults who are prescribed Norditropin®. Specific objectives include: 1) developing models defining the relationship of Norditropin dose to changes in insulin-like growth factor (IGF-I) and treatment outcomes, accounting for independent factors such as age, gender and puberty and 2) determining the relative predictive values of peak growth hormone (GH) and IGF-I levels and other factors before treatment to clinical outcomes.
Conditions Studied
Interventions
- DRUG somatropin
Study Locations (1)
New Jersey
- Novo Nordisk Investigational Site - Plainsboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,960 participants |
| Start Date | 2002-06-24 |
| Est. Completion | 2016-09-30 |
What the finished NCT01009905 record still lists
NCT01009905 is an observational study that tracks outcomes without assigning an intervention. Its 22,960 participants enrollment target places it among the larger protocols in the corpus, above the 32-participant average among 3 other Hypopituitarism trials with a reported enrollment target (71650% higher).
The record links to 3 conditions, with Hypopituitarism appearing as the primary indexed condition, and to 1 intervention - of which somatropin is the first listed.
NCT01009905 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT01009905 about?
NCT01009905 is a clinical study titled "An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)". This study is conducted in the United States of America (USA). The aim of this observational study is to collect data concerning the treatment outcomes and safety for children and adults who are prescribed Norditropin®. Specific objectives include: 1) developing models defining the relationship of N...
What is the current status of trial NCT01009905?
This trial is currently completed. The enrollment target is 22,960 participants. The study started on 2002-06-24. Estimated completion is 2016-09-30.
What conditions does trial NCT01009905 study?
This clinical trial studies the following conditions: Hypopituitarism, Growth Hormone Disorder, Pituitary Dwarfism.
What interventions are being tested in trial NCT01009905?
The interventions under investigation include: somatropin (DRUG).
Who is sponsoring clinical trial NCT01009905?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01009905 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypopituitarism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI